(Q37682520)

English

Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome

scientific article published on 27 January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

inflammatory bowel diseases

0 references

0 references

0 references

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Irene Lenoir-Wijnkoop

6

object named as

Irene Lenoir-Wijnkoop

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

4

object named as

Paul Enck

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Stig B.S. Bengmark

3

object named as

Stig Bengmark

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

author name string

Jean-Michel Antoine

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Ger T Rijkers

5

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

language of work or name

0 references

publication date

27 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Journal of Nutrition

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

140

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

690S-7S

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Clinical relevance of advances in genetics and pharmacogenetics of IBD.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

The immunological and genetic basis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Crohn's disease is associated with a toll-like receptor-9 polymorphism

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Functional variants of OCTN cation transporter genes are associated with Crohn disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

MDR1 Ala893 polymorphism is associated with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Genetic variation in DLG5 is associated with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Recent trends in the epidemiology of inflammatory bowel diseases: up or down?

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Mucosal flora in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

The primary defect in experimental ileitis originates from a nonhematopoietic source

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Saccharomyces boulardii in maintenance treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Probiotics and Crohn's disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Effects of probiotic on intestinal mucosa of patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

High-dose probiotics for the treatment of active pouchitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Functional bowel disorders

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Gastric distension and duodenal lipid infusion modulate intestinal gas transit and tolerance in humans

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Prebiotics, probiotics, and dietary fiber in gastrointestinal disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Review article: probiotics and prebiotics in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Meta-analysis of probiotics for the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Design of treatment trials for functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.3945%2FJN.109.113746

21 January 2018

Identifiers

10.3945/JN.109.113746

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37682520&oldid=1959738390"